Navigation Links
Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
Date:11/25/2008

SUNNYVALE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the company has completed a Phase 1 clinical trial with PCI-27483, the company's novel, first-in-class small-molecule Factor VIIa inhibitor. The trial was conducted in sixteen (16) healthy volunteers to evaluate the safety and pharmacologic effect of PCI-27483. A single administration of PCI-27483 resulted in a linear dose response in the International Normalized Ratio (INR), a routine laboratory test used to assess the level of anticoagulation (blood-thinning).

"Single doses of PCI-27483 reliably and quickly achieved therapeutic levels of anticoagulation without adverse effects in this initial trial," said James Lowder, M.D., Vice President, Clinical Development for Pharmacyclics. "The ability to achieve precise levels of anticoagulation that can be readily measured differentiates PCI-27483 from other available anticoagulants. The Factor VIIa: tissue factor complex, the pharmacologic target of PCI-27483, has been implicated both in the progression of solid tumors and the increased incidence of venous thromboembolic events observed in many malignancies. Up-regulation of tissue factor expression is observed in pancreatic, lung, and breast cancer, and is associated with a worsened prognosis."

In the recently completed study, PCI-27483 increased the INR with minimal intra-subject variation and a half-life of ten hours. At the highest subcutaneous dose of PCI-27483 evaluated, a mean (+/-standard error) peak INR of 2.72 (+/- 0.24) was achieved one to two hours post-dosing. The trial further established doses of PCI-27483, which upon repeated dosing are expected to maintain the INR in the range of 2.0 to 3.0, the target window for treatment and prevention of thromboembolic events (i.e., formation of blood clots).


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 NxStage Medical, ... of innovative dialysis products, announced today that the ... its System One™ to perform hemodialysis overnight while ... home nocturnal hemodialysis. NxStage,s® System One is the ... FDA for this indication. Home ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ... "Investment Analysis of the US Medical Device Sector ... http://photos.prnewswire.com/prnh/20130307/600769 This ... sector identifies the key trends and rationale for ... mergers and acquisitions. The study will ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today issued the following open letter to shareholders ... Dr. Med. Sc. Dear RXi Shareholders, ... number of inaccurate statements posted on certain social ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... Reportlinker.com announces that a new market research ... Clinical Laboratory Testing Volume 1: Reagents and ... Clinical laboratory analysis for in vitro diagnostic ... sectors of medical care. By all accounts, it ...
... Aug. 25 Millennium Research Group (MRG), the global ... venous procedures are set to grow by more than ... physicians is a major roadblock in increased interventions in ... specialists are increasingly adopting new technologies, with 55% of ...
Cached Medicine Technology:Reportlinker Adds Clinical Laboratory Testing Volume 1: Reagents and Instruments 2Physician Referrals Limiting Treatment of the Venous System 2Physician Referrals Limiting Treatment of the Venous System 3
(Date:12/25/2014)... months the trends for evening dresses shift and ... of the hottest styles in the next few months.” The ... 26 A-line sweetheart evening dresses, and announces the availability of ... trying our best to help a lady to show off ... prices, we provide discounted delivery costs to our customers worldwide. ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, Dylan ... dresses, has excitedly released its collection of discounted prom ... to Percy, a senior spokesman of the company, the ... of this promotion is to expand the UK market. ... in several different colors, lengths, and styles: A-line strapless, ...
(Date:12/25/2014)... BellasDress has launched its Christmas Sale, offering ... chosen their best-selling lace wedding dresses, vintage bridesmaid dresses ... , Now, BellasDress.com features popular women’s dresses, and ... prices. The business hopes everyone can have a memorable ... “All our elegant products are made with exquisite materials; ...
(Date:12/25/2014)... Woodland Hills, California (PRWEB) December 25, 2014 ... in her home in Woodland Hills, California after an ... Harris passed away on Christmas Eve evening in her ... battle with aggressive metastatic breast cancer. ... International for over forty years, she pioneered and championed ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Recently, LunaDress.co.uk has updated ... dresses and related accessories. Now, all of the models at LunaDress.co.uk ... moment a groom lifts the wedding veil can turn out to ... stunning charm. A wedding veil can always bring surprise to a ... suggestions on how to choose veils for a big day ...
Breaking Medicine News(10 mins):Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2
... suggests that a minimally invasive approach may accurately determine ... study in the February 6 issue of JAMA. , ... death in the United States. Determining the stage of ... prognosis, according to background information in the article. ...
... Income, SALT LAKE CITY, Feb. 5 Sonic Innovations,Inc. ... hearing aids,today announced results for the fourth quarter 2007. Net ... 12.4% over the $28.7 million,for the fourth quarter of 2006. ... over the $105.5 million for the year 2006. The,auditory testing ...
... 5 John Wagner,Director of the California ... implementation of the Cooperative Homeless Office-Initiated,Consultative Examination ... and reduce the length of time necessary ... California,s homeless population. In,essence, the CHOICE process ...
... downtown Las Vegan, LAS VEGAS, Feb. 5 If ... celebrities and the lucky few., Well ... Dr. Azimi ... reserved the dental chair for one lucky,person for a total ... agreed to donate a smile makeover to,a worthy candidate., ...
... finds, , , TUESDAY, Feb. 5 (HealthDay News) -- Pot smokers ... do, such as an increased risk of heart disease, but ... destroy gum tissue. , In the Feb. 6 issue ... researchers reported that heavy marijuana users have as much as ...
... Groups come together for National Black HIV/AIDS Awareness ... coordination with,National Black HIV/AIDS Awareness Day this Thursday, ... Fenty, the,Washington Wizards and Verizon Washington, DC have ... provide free and confidential testing events to,encourage residents ...
Cached Medicine News:Health News:Less invasive methods may provide accurate means to determine lung cancer stage 2Health News:Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 2Health News:Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 3Health News:Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 4Health News:Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 5Health News:Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 6Health News:Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 7Health News:California Department of Social Services Announces Improved Access to Disability Payments to Homeless Individuals 2Health News:A Downtown Las Vegas Dental Makeover by Dr. Azimi for the Most Deserving Resident or Working Professional 2Health News:Marijuana Bad for the Gums 2Health News:Marijuana Bad for the Gums 3Health News:Congresswoman Norton, Mayor Fenty, Verizon and the Washington Wizards Join the Test for Life Campaign to Encourage HIV Screenings in DC 2Health News:Congresswoman Norton, Mayor Fenty, Verizon and the Washington Wizards Join the Test for Life Campaign to Encourage HIV Screenings in DC 3
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Steroid eluting pacemaker leads...
VascoStim B 2/5F is a bipolar temporary pacing lead with a balloon. It can be placed easily by the resistance of the inflated balloon in the blood flow....
Medicine Products: